Flash CGM associated with event reduction in nonintensive diabetes therapy

Area of Science:

• Endocrinology
• Diabetes Management
• Health Informatics

Background:

• Type 2 diabetes (T2D) management often involves basal insulin or noninsulin therapies.
• Continuous Glucose Monitoring (CGM) systems are increasingly adopted for diabetes self-management.
• Evaluating the impact of flash CGM acquisition on clinical outcomes in T2D is crucial.

Purpose of the Study:

• To assess the effect of acquiring a flash CGM system on acute diabetes-related events (ADEs) and all-cause inpatient hospitalizations (ACHs).
• To analyze these effects in a population with T2D using basal or noninsulin therapy.

Main Methods:

• Retrospective database analysis using IBM MarketScan Commercial Claims and Medicare Supplemental databases.
• Inclusion criteria: T2D diagnosis, age ≥18, treated with basal insulin or noninsulin therapy, CGM-naïve, flash CGM acquired between Oct 2017-Mar 2019.
• Comparison of ADE and ACH rates 6 months pre- and post-CGM acquisition using weighted Cox regression.

Main Results:

• A cohort of 10,282 adults with T2D was analyzed.
• Flash CGM acquisition was associated with a significant decrease in ADE rates (0.076 to 0.052 events/patient-year; HR 0.68).
• Significant reductions were also observed in ACH rates (0.177 to 0.151 events/patient-year; HR 0.85).

Conclusions:

• Acquisition of flash CGM systems led to significant reductions in both outpatient and inpatient ADEs and ACHs.
• Flash CGM use in T2D patients on basal insulin or noninsulin therapy improves clinical outcomes.
• These findings suggest potential healthcare cost reductions associated with flash CGM implementation.